Nachrichten zur BridgeBio Pharma Inc. Aktie

–Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) continues to have high operating fidelity; month 30…

Kumar, Neil - Vorstand - Tag der Transaktion: 2023-02-17...…

Stephenson, Brian C. - Vorstand - Tag der Transaktion: 2023-02-17...…

PALO ALTO, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”),…

BridgeBio Pharma (BBIO) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…

PALO ALTO, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”),…

Stephenson, Brian C. - Vorstand - Tag der Transaktion: 2023-02-03...…

Kumar, Neil - Vorstand - Tag der Transaktion: 2023-02-03...…

Stephenson, Brian C. - Vorstand - Tag der Transaktion: 2023-01-05...…

Kumar, Neil - Vorstand - Tag der Transaktion: 2023-01-05...…

PALO ALTO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”),…